Diagnostic Industry Trends Hinge On Gene-Based Tests
In 2011, sequencing was once again the big story in diagnostics. But unlike 2010 when the big news was the successful IPOs of next-generation sequencing companies Pacific Biosciences and Complete Genomics, the tone in 2011 was more nuanced.
You may also be interested in...
Genomics Through The Lens Of Precompetitive Data Sharing
With low-cost whole genome sequencing on the horizon, issues around acquiring and assessing large data sets of sequence information are front and center. The value proposition is also shifting, from the means of acquiring data to their interpretation. But finding a sustainable business model around data analysis and clinical services is far from straightforward.
Molecular Dx Reimbursement: Medicare Contractor Seeks Tighter Controls
West Coast contractor Palmetto issues draft proposal establishing a"non-coverage" policy for molecular tests not explicitly covered by Palmetto or a national CMS directive.